These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30372691)

  • 1. Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Pirosa MC; Leotta S; Cupri A; Stella S; Martino EA; Scalise L; Sapienza G; Calafiore V; Mauro E; Spadaro A; Vigneri P; Di Raimondo F; Milone G
    Chemotherapy; 2018; 63(4):220-224. PubMed ID: 30372691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
    Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph'+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib.
    Molica M; Mazzone C; Cordone I; Divona M; Niscola P; de Fabritiis P
    Chemotherapy; 2021; 66(3):78-81. PubMed ID: 34102636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
    He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
    Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.
    Tachibana T; Tanaka M; Noguchi Y; Najima Y; Sadato D; Harada Y; Tamai Y; Doki N; Nakajima H
    Hematology; 2024 Dec; 29(1):2360843. PubMed ID: 38828928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
    Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
    Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yamamoto M; Hori T; Igarashi K; Shimada H; Tsutsumi H
    Pediatr Int; 2018 Jan; 60(1):85-87. PubMed ID: 29356285
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
    Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
    Petrungaro A; Gentile M; Mazzone C; Greco R; Uccello G; Recchia AG; De Stefano L; Bossio S; Palummo A; Morelli R; Musolino C; Morabito F; Vigna E
    Chemotherapy; 2017; 62(6):353-356. PubMed ID: 28810255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?
    Sohn SK; Lee JM; Jang Y; Lee Y; Na J; Cho HJ; Moon JH; Baek DW
    Expert Rev Hematol; 2024 Jul; 17(7):353-359. PubMed ID: 38755522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
    Short NJ; Kantarjian H; Jabbour E; Ravandi F
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
    Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
    Wieduwilt MJ
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies.
    Huang Z; Zhang Y; Chen J; Shi Y; Chen P; Jiang S; Qian H
    Am J Case Rep; 2024 Aug; 25():e944956. PubMed ID: 39099157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.
    Yoshimitsu M; Fujiwara H; Ozaki A; Hamada H; Matsushita K; Arima N; Tei C
    Int J Hematol; 2008 Oct; 88(3):331-335. PubMed ID: 18696183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Othman T; Koller P; Tsai NC; Yang D; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Spielberger R; Sahebi F; Al Malki MM; Cai JL; Sandhu KS; Mansour J; Salhotra A; Ali H; Aribi A; Arslan S; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Aldoss I; Mei M
    Am J Hematol; 2024 Sep; 99(9):1680-1690. PubMed ID: 38804599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.